Deciphera’s Vimseltinib Could Benefit From Liver Safety, Prescriber Overlap in TGCT

Positive topline results from the Phase III MOTION trial showed none of the liver toxicity that earned Daiichi Sankyo’s Turalio a boxed warning and REMS in tenosynovial giant cell tumor.

Deciphera Pharmaceuticals, Inc.’s Phase III vimseltinib has a potentially smooth path to market in tenosynovial giant cell tumor (TGCT) thanks to a safety profile more benign than a competing drug for the condition already on the market. Decipher should also benefit from marketing to physicians that mostly overlaps with the one that Deciphera targets for its drug for gastrointestinal stromal tumors (GIST).

The Waltham, MA-based company announced 30 October positive topline results from the Phase III MOTION study of vimseltinib as well as updated Phase I/II results from a study of the...

Key Takeaways

Vimseltinib showed a positive improvement in objective response rate compared with placebo in the Phase III MOTION trial, but no cholestatic hepatotoxicity.
The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.